BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+10.77%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.78B
AUM Growth
+$3.78B
(+9.1%)
Cap. Flow
+$24M
Cap. Flow
% of AUM
0.63%
Top 10 Holdings %
Top 10 Hldgs %
64.41%
Holding
33
New
1
Increased
14
Reduced
7
Closed
1
Top Buys
| 1 |
Exelixis
EXEL
|
$30.6M |
| 2 |
argenx
ARGX
|
$21.7M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$20.1M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$19.7M |
| 5 |
Nektar Therapeutics
NKTR
|
$19.5M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$32.4M |
| 2 |
CELG
Celgene Corp
CELG
|
$30.4M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$28.3M |
| 4 |
Neurocrine Biosciences
NBIX
|
$19.6M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$15.5M |
Sector Composition
| 1 | Healthcare | 96.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $447M | 11.83% | 8,666,334 | – | – |
|
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $388M | 10.28% | 3,158,090 -159,663 | -5% | -$19.6M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $267M | 7.07% | 2,984,298 -340,000 | -10% | -$30.4M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $264M | 6.99% | 1,370,445 -30,000 | -2% | -$5.78M |
|
5
Incyte
INCY
$16.5B
| $263M | 6.96% | 3,808,322 +50,000 | +1% | +$3.45M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $183M | 4.84% | 1,314,428 -30,000 | -2% | -$4.17M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $170M | 4.49% | 2,197,931 | – | – |
|
|
SAGE
8
DELISTED
Sage Therapeutics
SAGE
| $151M | 4% | 1,071,373 | – | – |
|
|
9
Gilead Sciences
GILD
$140B
| $151M | 3.99% | 1,954,596 -420,000 | -18% | -$32.4M |
|
10
Halozyme
HALO
$8.56B
| $150M | 3.97% | 8,247,860 | – | – |
|
11
Esperion Therapeutics
ESPR
$448M
| $146M | 3.85% | 3,282,964 +100,000 | +3% | +$4.44M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $120M | 3.17% | 1,370,538 +230,000 | +20% | +$20.1M |
|
|
RDUS
13
DELISTED
Radius Health, Inc.
RDUS
| $117M | 3.1% | 6,590,276 +389,363 | +6% | +$6.93M |
|
|
TSRO
14
DELISTED
TESARO, Inc.
TSRO
| $114M | 3.03% | 2,931,802 +505,000 | +21% | +$19.7M |
|
|
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
| $94.7M | 2.51% | 3,567,882 +60,000 | +2% | +$1.59M |
|
|
AKCA
16
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $83.6M | 2.21% | 2,386,471 -97,600 | -4% | -$3.42M |
|
|
17
Regeneron Pharmaceuticals
REGN
$61.5B
| $80.8M | 2.14% | 200,000 -70,000 | -26% | -$28.3M |
|
18
Wave Life Sciences
WVE
$1.53B
| $69.3M | 1.83% | 1,385,002 +247,117 | +22% | +$12.4M |
|
|
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $69M | 1.82% | 545,719 | – | – |
|
20
MacroGenics
MGNX
$112M
| $64.1M | 1.7% | 2,990,412 +330,000 | +12% | +$7.08M |
|
|
21
argenx
ARGX
$43.6B
| $55.7M | 1.47% | 734,739 +285,690 | +64% | +$21.7M |
|
22
Voyager Therapeutics
VYGR
$186M
| $53.4M | 1.41% | 2,822,641 +290,000 | +11% | +$5.49M |
|
|
23
Nektar Therapeutics
NKTR
$568M
| $51.5M | 1.36% | 845,000 +320,000 | +61% | +$19.5M |
|
|
24
Exelixis
EXEL
$10.1B
| $49.4M | 1.31% | 2,785,000 +1,725,000 | +163% | +$30.6M |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $47.7M | 1.26% | 2,200,000 | – | – |
|